ERBB2 in anti-EGFR-resistant colorectal cancer: cancer stem cells come into play
- 22 February 2021
- Vol. 71 (1), 4-5
- https://doi.org/10.1136/gutjnl-2020-323924
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cellsGut, 2021
- Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotypeScience Translational Medicine, 2020
- Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variantOncogene, 2019
- Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer modelsJournal of Experimental & Clinical Cancer Research, 2019
- Stem cells in homeostasis and cancer of the gutMolecular Cancer, 2019
- The genomic landscape of response to EGFR blockade in colorectal cancerNature, 2015
- Resistance to dual blockade of the kinases PI3K and mTOR in KRAS -mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFRScience Signaling, 2014
- CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer MetastasisCell Stem Cell, 2014
- A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal CancerCancer Discovery, 2011
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabScience Translational Medicine, 2011